JP7249962B2 - がんを治療するための液体剤形 - Google Patents

がんを治療するための液体剤形 Download PDF

Info

Publication number
JP7249962B2
JP7249962B2 JP2019567635A JP2019567635A JP7249962B2 JP 7249962 B2 JP7249962 B2 JP 7249962B2 JP 2019567635 A JP2019567635 A JP 2019567635A JP 2019567635 A JP2019567635 A JP 2019567635A JP 7249962 B2 JP7249962 B2 JP 7249962B2
Authority
JP
Japan
Prior art keywords
compound
malate
pharmaceutically acceptable
acceptable salt
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019567635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523317A5 (enExample
JP2020523317A (ja
Inventor
カリード シャー，
ギセラ シュワブ，
スティーブン レイシー，
Original Assignee
エグゼリクシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エグゼリクシス， インコーポレイテッド filed Critical エグゼリクシス， インコーポレイテッド
Publication of JP2020523317A publication Critical patent/JP2020523317A/ja
Publication of JP2020523317A5 publication Critical patent/JP2020523317A5/ja
Application granted granted Critical
Publication of JP7249962B2 publication Critical patent/JP7249962B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019567635A 2017-06-09 2018-06-08 がんを治療するための液体剤形 Active JP7249962B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762517736P 2017-06-09 2017-06-09
US62/517,736 2017-06-09
US201762520768P 2017-06-16 2017-06-16
US62/520,768 2017-06-16
PCT/US2018/036703 WO2018227119A1 (en) 2017-06-09 2018-06-08 Liquid dosage forms to treat cancer

Publications (3)

Publication Number Publication Date
JP2020523317A JP2020523317A (ja) 2020-08-06
JP2020523317A5 JP2020523317A5 (enExample) 2021-07-26
JP7249962B2 true JP7249962B2 (ja) 2023-03-31

Family

ID=62779087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019567635A Active JP7249962B2 (ja) 2017-06-09 2018-06-08 がんを治療するための液体剤形

Country Status (10)

Country Link
US (3) US11504362B2 (enExample)
EP (1) EP3634413A1 (enExample)
JP (1) JP7249962B2 (enExample)
KR (1) KR102647794B1 (enExample)
CN (1) CN110678180A (enExample)
AU (1) AU2018279834B2 (enExample)
CA (1) CA3065560A1 (enExample)
MX (1) MX2019014298A (enExample)
UA (1) UA126402C2 (enExample)
WO (1) WO2018227119A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA033513B1 (ru) * 2011-02-10 2019-10-31 Exelixis Inc Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения
CN110678180A (zh) 2017-06-09 2020-01-10 埃克塞里艾克西斯公司 治疗癌症的液体剂型
SG11202006921PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CN120417903A (zh) 2023-01-31 2025-08-01 汉达癌症医药责任有限公司 改良的卡博替尼组合物及其使用方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512416A (ja) 1999-10-25 2003-04-02 スーパージェン インコーポレイテッド パクリタクセル用の新規且つ改善された組成物
JP2005343897A (ja) 2004-06-02 2005-12-15 Cordis Corp Ｃａｄ治療のためのタキサンの注入可能な配合物
JP2013540805A (ja) 2010-10-29 2013-11-07 トロイカ ファーマスーティカルズ リミテッド ビタミンｂ１２の鼻内用組成物
JP2014513129A (ja) 2011-05-02 2014-05-29 エクセリクシス， インク． 癌および骨癌疼痛の治療方法
JP2015523400A (ja) 2012-07-27 2015-08-13 バント，アントニウス，マルティヌス ガステーブ 排出阻害剤およびこれを用いる治療法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
US20080200515A1 (en) 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
DK2387563T4 (da) * 2009-01-16 2022-07-18 Exelixis Inc Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
EP2758057B1 (en) * 2011-09-22 2017-05-31 Exelixis, Inc. Method for treating osteoporosis
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
MX384828B (es) 2014-02-14 2025-03-14 Exelixis Inc Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
US20170042880A1 (en) 2014-04-25 2017-02-16 Exelixis, Inc. Method of Treating Lung Adenocarcinoma
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
CN110678180A (zh) 2017-06-09 2020-01-10 埃克塞里艾克西斯公司 治疗癌症的液体剂型

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512416A (ja) 1999-10-25 2003-04-02 スーパージェン インコーポレイテッド パクリタクセル用の新規且つ改善された組成物
JP2005343897A (ja) 2004-06-02 2005-12-15 Cordis Corp Ｃａｄ治療のためのタキサンの注入可能な配合物
JP2013540805A (ja) 2010-10-29 2013-11-07 トロイカ ファーマスーティカルズ リミテッド ビタミンｂ１２の鼻内用組成物
JP2014513129A (ja) 2011-05-02 2014-05-29 エクセリクシス， インク． 癌および骨癌疼痛の治療方法
JP2015523400A (ja) 2012-07-27 2015-08-13 バント，アントニウス，マルティヌス ガステーブ 排出阻害剤およびこれを用いる治療法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DRUG METABOLISM AND DISPOSITION，2015年，43(8)，pp.1190 - 1207
JOURNAL OF CLINICAL ONCOLOGY，2011年，29(19)，pp.2660 - 2666

Also Published As

Publication number Publication date
WO2018227119A1 (en) 2018-12-13
UA126402C2 (uk) 2022-09-28
EP3634413A1 (en) 2020-04-15
US20240307367A1 (en) 2024-09-19
US20200268737A1 (en) 2020-08-27
AU2018279834A1 (en) 2020-01-16
BR112019025110A2 (pt) 2020-09-01
JP2020523317A (ja) 2020-08-06
US20230301978A1 (en) 2023-09-28
CA3065560A1 (en) 2018-12-13
US11504362B2 (en) 2022-11-22
KR20200014903A (ko) 2020-02-11
KR102647794B1 (ko) 2024-03-15
CN110678180A (zh) 2020-01-10
MX2019014298A (es) 2020-02-03
US12016854B2 (en) 2024-06-25
AU2018279834B2 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
JP7249962B2 (ja) がんを治療するための液体剤形
Abel et al. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects
US12036224B2 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
JP2016515628A (ja) 癌を治療するための複合薬
EP3984523A1 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
US20110263716A1 (en) Colchine compositions and methods
TW201731509A (zh) 針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案
WO2004054574A1 (ja) 経口固形医薬
JP2022044699A (ja) ヒドロキシピリドネートアクチニド／ランタニド体外除去剤の製剤
Ermer et al. Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release
Gunn et al. Translational characterization of [11C] GSK931145, a PET ligand for the glycine transporter type 1
JP2024523559A (ja) アルドステロン合成酵素阻害剤を使用する方法
WO2022106621A1 (en) Selexipag for use via intracolonic administration
Stewart et al. Synthesis and pre-clinical evaluation of a potential radiotracer for PET imaging of the dopamine D 3 receptor
EA043824B1 (ru) Жидкие лекарственные формы для лечения рака
BR112019025110B1 (pt) Composição farmacêutica líquida e seus usos
Kshirsagar et al. Mass Balance, Metabolic Pathways, Absolute Bioavailability, and Pharmacokinetics of Giredestrant in Healthy Subjects
Kim et al. The use of healthy volunteers instead of patients to inform drug dosing studies: a [11C] raclopride PET study
Pardo et al. A single-dose, comparative bioavailability study comparing amphetamine extended-release oral suspension with extended-release mixed amphetamine salts capsules
McCarthy Positron emission tomography imaging as a key enabling technology in drug development
JP2025519466A (ja) フロログルシノール製剤および使用方法
Patel et al. Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers
Wines et al. Drug Class Review Alzheimer’s Drugs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220331

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230320

R150 Certificate of patent or registration of utility model

Ref document number: 7249962

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150